Home › Borstkanker › Virginia › Norfolk
Borstkanker klinische studies in Norfolk, VA
16 studies voor Borstkanker zoeken deelnemers op locaties in en rond Norfolk (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruterenGezonde vrijwilligers welkom
- Sentara Norfolk General Hospital, Norfolk
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RekruterenFase 3
- Virginia Oncology Associates, Norfolk
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RekruterenFase 3
- Virginia Oncology Associates, Norfolk
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Sentara Norfolk General Hospital, Norfolk
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
RekruterenFase 2
- Virginia Oncology Associates, Norfolk
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
RekruterenFase 1/2
- Virginia Oncology Associates, Norfolk
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RekruterenFase 3
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RekruterenFase 3
- Research Site, Norfolk
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruterenFase 3
- Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RekruterenFase 3
- Clinical Trial Site, Norfolk
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
RekruterenFase 2
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RekruterenFase 1/2
- Virginia Cancer Institute, Norfolk
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
RekruterenFase 1/2
- Virginia Oncology Associates (Norfolk) - USOR, Norfolk
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RekruterenFase 3
- Virginia Oncology Associates, Norfolk
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruterenFase 1/2
- USOR Virginia Oncology Associates, Norfolk
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
RekruterenFase 2
- Virginia Oncology Associates, Norfolk
Borstkanker studies in andere steden
- New York City, NY136 studies
- Houston, TX126 studies
- Boston, MA112 studies
- Nashville, TN81 studies
- Los Angeles, CA73 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Queens, NY64 studies
- Durham, NC64 studies
- Chicago, IL59 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Andere studies in Norfolk
- Blasenkanker8 studies
- Prostaatkanker8 studies
- Abdominaal aorta-aneurysma7 studies
- Eierstokkanker7 studies
- Niet-kleincellige longkanker7 studies
- Kanker (alle vormen)7 studies
- Hartfalen7 studies
- Cardiovasculaire ziekte7 studies
- Spinale musculaire atrofie6 studies
- Perifere arteriële ziekte5 studies
- Drievoudig negatieve borstkanker5 studies
- Acute myeloïde leukemie5 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.